Literature DB >> 28830982

Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells.

Chuay-Yeng Koo1, Caterina Giacomini1, Marta Reyes-Corral1, Yolanda Olmos1, Ignatius A Tavares1, Charles M Marson2, Spiros Linardopoulos3, Andrew N Tutt3,4, Jonathan D H Morris5.   

Abstract

Thousand-and-one amino acid kinases (TAOK) 1 and 2 are activated catalytically during mitosis and can contribute to mitotic cell rounding and spindle positioning. Here, we characterize a compound that inhibits TAOK1 and TAOK2 activity with IC50 values of 11 to 15 nmol/L, is ATP-competitive, and targets these kinases selectively. TAOK inhibition or depletion in centrosome-amplified SKBR3 or BT549 breast cancer cell models increases the mitotic population, the percentages of mitotic cells displaying amplified centrosomes and multipolar spindles, induces cell death, and inhibits cell growth. In contrast, nontumorigenic and dividing bipolar MCF-10A breast cells appear less dependent on TAOK activity and can complete mitosis and proliferate in the presence of the TAOK inhibitor. We demonstrate that TAOK1 and TAOK2 localize to the cytoplasm and centrosomes respectively during mitosis. Live cell imaging shows that the TAOK inhibitor prolongs the duration of mitosis in SKBR3 cells, increases mitotic cell death, and reduces the percentages of cells exiting mitosis, whereas MCF-10A cells continue to divide and proliferate. Over 80% of breast cancer tissues display supernumerary centrosomes, and tumor cells frequently cluster extra centrosomes to avoid multipolar mitoses and associated cell death. Consequently, drugs that stimulate centrosome declustering and induce multipolarity are likely to target dividing centrosome-amplified cancer cells preferentially, while sparing normal bipolar cells. Our results demonstrate that TAOK inhibition can enhance centrosome declustering and mitotic catastrophe in cancer cells, and these proteins may therefore offer novel therapeutic targets suitable for drug inhibition and the potential treatment of breast cancers, where supernumerary centrosomes occur. Mol Cancer Ther; 16(11); 2410-21. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28830982     DOI: 10.1158/1535-7163.MCT-17-0077

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  17 in total

1.  The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin.

Authors:  Samriddhi Shukla; David Milewski; Arun Pradhan; Nihar Rama; Kathryn Rice; Tien Le; Matthew J Flick; Sara Vaz; Xueheng Zhao; Kenneth D Setchell; Elsa Logarinho; Vladimir V Kalinichenko; Tanya V Kalin
Journal:  Mol Cancer Ther       Date:  2019-04-30       Impact factor: 6.261

Review 2.  Giants and monsters: Unexpected characters in the story of cancer recurrence.

Authors:  Shai White-Gilbertson; Christina Voelkel-Johnson
Journal:  Adv Cancer Res       Date:  2020-05-04       Impact factor: 6.242

3.  Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy.

Authors:  Matthew B Lipner; Xianlu L Peng; Chong Jin; Yi Xu; Yanzhe Gao; Michael P East; Naim U Rashid; Richard A Moffitt; Silvia G Herrera Loeza; Ashley B Morrison; Brian T Golitz; Cyrus Vaziri; Lee M Graves; Gary L Johnson; Jen Jen Yeh
Journal:  JCI Insight       Date:  2020-04-23

4.  Aggressive uveal melanoma displays a high degree of centrosome amplification, opening the door to therapeutic intervention.

Authors:  Dorota Sabat-Pośpiech; Kim Fabian-Kolpanowicz; Helen Kalirai; Natalie Kipling; Sarah E Coupland; Judy M Coulson; Andrew B Fielding
Journal:  J Pathol Clin Res       Date:  2022-04-26

5.  A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.

Authors:  Caterina Giacomini; Chuay-Yeng Koo; Natalia Yankova; Ignatius A Tavares; Selina Wray; Wendy Noble; Diane P Hanger; Jonathan D H Morris
Journal:  Acta Neuropathol Commun       Date:  2018-05-07       Impact factor: 7.801

6.  Identification of a dual TAOK1 and MAP4K5 inhibitor using a structure-based virtual screening approach.

Authors:  Min-Wu Chao; Tony Eight Lin; Wei-Chun HuangFu; Chao-Di Chang; Huang-Ju Tu; Liang-Chieh Chen; Shih-Chung Yen; Tzu-Ying Sung; Wei-Jan Huang; Chia-Ron Yang; Shiow-Lin Pan; Kai-Cheng Hsu
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

7.  Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy.

Authors:  Michael Y He; Michael M Halford; Ruofei Liu; James P Roy; Zoe L Grant; Leigh Coultas; Niko Thio; Omer Gilan; Yih-Chih Chan; Mark A Dawson; Marc G Achen; Steven A Stacker
Journal:  Commun Biol       Date:  2021-07-15

8.  Transcriptome analysis reveals gender-specific differences in overall metabolic response of male and female patients in lung adenocarcinoma.

Authors:  Ya Li; Cheng-Lu He; Wen-Xing Li; Rui-Xian Zhang; Yong Duan
Journal:  PLoS One       Date:  2020-04-01       Impact factor: 3.240

9.  Tryptone-stabilized gold nanoparticles induce unipolar clustering of supernumerary centrosomes and G1 arrest in triple-negative breast cancer cells.

Authors:  J Grace Nirmala; Manu Lopus
Journal:  Sci Rep       Date:  2019-12-13       Impact factor: 4.379

Review 10.  The Diverse Roles of TAO Kinases in Health and Diseases.

Authors:  Chih-Yeu Fang; Tsung-Ching Lai; Michael Hsiao; Yu-Chan Chang
Journal:  Int J Mol Sci       Date:  2020-10-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.